Description:
Reference #: 01566
The University of South Carolina is offering licensing opportunities for Blood-cytokine levels as adverse outcome predictors following biomaterial implant surgery
Background:
Despite the high number of patients undergoing reconstruction surgery with surgical mesh and the relatively high number of adverse outcomes, there are currently no published methods to predict undesired outcomes of this surgery. In addition, adverse outcomes remain a possibility for other reconstruction surgeries with surgical mesh or other implant materials.
Invention Description:
This invention is a method that utilizes a patient’s blood sample to predict undesired surgical outcomes, which can then help surgeons and patients to make a better-informed decision on whether to proceed with surgery.
Potential Applications:
This innovative blood test can be performed using a patient’s blood sample to provide information about whether the patient might have an adverse surgical event.
Advantages and Benefits:
This innovation provides a not yet available means by which to minimize risk of adverse outcomes following biomaterial implant surgery, including but not limited to surgery to correct pelvic organ prolapse (POP).